Seroprevalence of hepatitis A and cost evaluation of different vaccination strategies against hepatitis A virus in patients with chronic hepatitis C in France

Pierre RUFAT (1), Patrice DUMOUCHEL (2), Jean-François CADRANEL (3)

(1) Cellule de Médicalisation du Système d’Information, Hôpital Beaujon, 92118 Clichy ; (2) Laboratoire d’Hémato-Immunologie, (3) Unité d’Hépatologie, Service d’Hépato-gastroentérologie et de Diabétologie, Centre Hospitalier Laennec, BP 72, 60109 Creil Cedex.

SUMMARY

Objectives — To prospectively determine the prevalence of total hepatitis virus A antibodies in patients with chronic hepatitis C and to evaluate the direct costs of several vaccination strategies against hepatitis A virus in these patients.

Methods — From April 1 to July the 31 1998, 219 patients with hepatitis C virus antibodies underwent a systematic testing for total hepatitis virus A antibodies (MEIA-AXSYM, Abbott laboratories). The prevalence of hepatitis A virus antibodies was evaluated according to age and suspected way of hepatitis C contamination. This prevalence has been compared to that in individuals undergoing a check-up provided by the national health insurance system stratified by age. Direct costs of 2 vaccination strategies “A” and “B” were evaluated according to age (< 40 vs > 40 years) and number of vaccine doses (1 or 2). “A” strategy included the systematic vaccination of all patients without determining the presence of total hepatitis A antibodies. “B” strategy included testing for total hepatitis A antibodies and vaccination of seronegative patients. The costs of these two strategies (A and B) were calculated with one and two vaccine doses.

Results — The prevalence of total hepatitis A antibodies was 76% in the entire population. It increased after the age of 35 and was statistically higher in patients who were older than 40 than in patients younger than 40. This prevalence was not significantly different from that in individuals who underwent a check-up provided by the national health insurance system stratified according to age. “B” strategy with 2 vaccine doses was less expensive that A strategy in the whole population and in patients younger than 40. This strategy was less expensive with 1 vaccine dose except in patients who had recently screened positive for hepatitis C antibodies younger than 40 when it induced an increased in direct cost due to the low prevalence of total hepatitis A antibodies in these patients.

Conclusions — In patients with hepatitis C antibodies with a high prevalence of total hepatitis A antibodies, testing for the prevalence of these antibodies before vaccination decreases the direct cost of this vaccination.
Seroprevalence of hepatitis A and cost evaluation of different vaccination strategies against hepatitis A virus in patients with chronic hepatitis C in France

Seroprevalence of total anti-HAV antibodies

Seroprevalence of HAV infection was determined first in the overall study population then by group. Seroprevalence of total anti-HAV antibodies was studied by age: 18-40 years versus >40 years. In the patients in group 2, who attended hepatology consultations, seroprevalence of anti-HAV antibodies was classified by presumed route of HCV contamination: intravenous drug use versus transfusion. The control population for comparing HAV prevalence in HCV-positive patients was taken from a prospective survey of subject attending check-up clinics provided by the national health insurance system [2]. This survey provides HAV seroprevalence data, independently of HCV serology, for the general French population which is similar to the population residing in the urban community around our center in Creil.

PROSPECTIVE EVALUATION OF VACCINATION COST

The direct cost of different vaccination strategies (figure 1) were determined in groups 1 and 2. Two strategies, A and B, were evaluated. Strategy A consisted of vaccination of all HCV-positive patients irrespective of prior HAV immunization. The cost of strategy A was evaluated for all patients in the study population and for groups 1 and 2, as well as in the subset of patients aged under 40 years. Cost was calculated using a 1-dose and a 2-dose vaccination scheme. Strategy B consisted of first determining HAV serology status then vaccinating HAV-negative subjects. Cost of this strategy was calculated in the same way as for strategy A, again with 1-dose and 2-dose schemes. The number of persons to vaccinate was taken as "N", i.e. the total number of persons in the study population for strategy A and N × (1-P) for strategy B, where P is the number of HAV-positive patients. The cost of determining anti-HAV total antibody status (D) (which is reimbursed by the national health insurance) was 19.2 euros (€) at the time of the study. The cost of a single dose of Havrix® (V) adult 1440 (not reimbursed by the national health insurance) was €44.2. The direct cost of strategy A was N × V and the direct cost of strategy B was N × D + N × (1-P) × V. In order for strategy B to be cost effective, the seroprevalence (P = prevalence of HAV-positive patients) of HAV infection would have to be at least P = D/V, all item costs being equivalent. This calculation was performed before determining the seroprevalence in our study population and led to the conclusion that seroprevalence of total anti-HAV antibodies would have to be at least 43% for strategy B to reach cost effectiveness for a 1-dose scheme (maximum number of patients to vaccinate = 57%) and at least 22% for a 2-dose scheme (maximum number of patients to vaccinate = 78%). The model applied used a single dose of vaccine (Havrix® adult 1440) with one initial injection and a booster six months later for the 2-dose scheme.

STATISTICS

Chi-square test or Fisher exact test as appropriate were used for qualitative variables and Student’s t test or Mann-Whitney test as appropriate for quantitative variables. Results are expressed as mean ± SD and in percentage with P < 0.05 considered as significant.

Results

Seroprevalence

Seroprevalence of total anti-HAV antibodies, reflecting immunization, was 76% (166 patients) in the study population. There was no difference in seroprevalence by gender. Seroprevalence was higher in patients older than 40 years than in patients aged 18-40 years (97% versus 51%, P < 10^{-4}). Seroprevalence in patients in group 2 contaminated by transfusion (n = 64) was higher than in patients contaminated by intravenous drug use (n = 68) (89% versus 63%, P < 10^{-2}), but this difference was no longer significant after adjustment for age. The seroprevalence of total anti-HAV antibodies in the entire study population and in groups 1 and 2 are presented in Table I. For a given age range, seroprevalence of HAV infection was higher in group 1 than in group 2 (P < 10^{-2}). The seroprevalence of anti-HAV antibodies in HCV-positive patients was not different from that observed in the control population stratified by age (chi-square = 0.84, NS) (table II), suggesting that HCV infection does not increase the risk of HAV infection. The seroprevalence of anti-HAV antibodies increased strongly above the age range 35 to 46 years (table II).

Direct cost of vaccination strategies

The direct cost of vaccination strategy A (systematic vaccination) and strategy B (vaccination after HAV screening) is detailed in tables III and IV by age and by number of vaccine doses.

Table I. – Prevalence of total hepatitis A antibodies in patients with hepatitis C antibodies.

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>18–40 yrs</th>
<th>&gt; 40 yrs</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients (n = 219)</td>
<td>76%</td>
<td>50%</td>
<td>95%</td>
<td>&lt; 10^{-6}</td>
</tr>
<tr>
<td>Group 1 (n = 43)</td>
<td>60%</td>
<td>37%</td>
<td>85%</td>
<td>&lt; 10^{-3}</td>
</tr>
<tr>
<td>Group 2 (n = 176)</td>
<td>80%</td>
<td>56%</td>
<td>97%</td>
<td>&lt; 10^{-4}</td>
</tr>
</tbody>
</table>

*Difference between patients aged 18–40 years and > 40 years.
Group 1: recently screened HCV+ patients; Group 2: patients attending hepatology consultations for chronic hepatitis C.
Discussion

The results of this study demonstrate that total anti-HAV seroprevalence in an urban population in France with chronic hepatitis C (mean age 47 years) is 76%. This seroprevalence is different from that observed in an age-stratified population of persons attending national insurance health care centers in the Center-West of France published in 1992 (table II) [2]. Although the population and study periods were different, these results do suggest that HCV infection is not a risk factor for HAV infection independently of the route of HCV contamination. Results in a recent North American study confirmed that increased HAV infection is not higher in HCV-infected subjects than in the general population [7]. The seroprevalence of HAV in our population of HCV-positive patients increased strongly with age, commencing at 45-46 years, as is observed in the general population. It was significantly higher in patients over 40 (95%) than in those under 40. Thus, in our population, 50% under 40 were not immunized against HAV, raising the theoretical risk of acute hepatitis A.

The potential gravity of hepatitis A in patients with chronic hepatitis C remains controversial [3, 4]. This study was designed after the publication by Vento et al. [3] of the high prevalence of fulminant hepatitis A in HCV-positive patients. In that Italian study, 7 out of 17 patients (45%) with acute hepatitis A developed a fatal disease which was fatal in 6 [3]. Four of these patients had a haplotype frequently found in autoimmune hepatitis (A1B8DR3) suggesting HAV superinfection induced a dysimmunization phenomenon in these patients [8]. The highly debated observations of this prospective study [9-11] were not found in other retrospective studies [11, 12]. Nonetheless, other prospective studies have confirmed the potential gravity of hepatitis A in patients with chronic liver disease [13]. Hepatitis A-related mortality increased from 3.4% to 27.5% in case of chronic liver disease and it was also noted that 60% of patients with chronic liver disease had cirrhosis [13]. In another study conducted in the United States [14], mortality from acute hepatitis A was 1.5% in patients free from chronic liver disease and reached 4.6% in patients with chronic liver disease [14]. These different studies have led United States health authorities to recommend anti-HAV vaccination for patients with chronic liver disease [5]. Apart from over mortality and independently of chronic liver disease, hepatitis A in adults frequently results in severe symptoms and often presents with prolonged cholestasis [13, 14].

Our model does not allow us to draw conclusions concerning the effect of HAV vaccination of non-immunized patients with chronic liver disease. Similarly, French or European health authorities have not provided precise recommendations. In the absence of such recommendations, French experts recently opted for an “intuitive principle of precaution” [17] proposing anti-HAV vaccination for HCV-positive and/or HBV-positive persons [17, 18]. In our opinion, anti-HAV vaccination should be proposed for all non-immunized patients with chronic liver disease caused by the hepatitis B or C virus, irrespective of the severity. There exists a cost problem however since HAV vaccination is not reimbursed by the national health insurance system. Future discussions with the health authorities should thus focus on this point.

The efficacy and safety of the anti-HAV vaccine (Havrix®) has been recently demonstrated in patients with chronic hepatitis C [19]. However, while 93% of the healthy subjects exhibited a
seroconversion with total anti-HAV antibodies after a single dose, this percentage was only 73.7% in patients with chronic hepatitis C. A 94% immunization rate is however obtained after complete vaccination, emphasizing the usefulness of two doses for these subjects [19]. In addition, the geometric antibody titer was lower in patients with chronic liver disease perhaps an expression of less effective protection. The duration of immunization after anti-HAV vaccination is approximately 20 years [in patients other than chronic liver disease] [18]. No data is available for patients with chronic liver disease [20]. Prospective studies are required to determine whether the level of immunization provided by anti-HAV vaccination is the same in patients with chronic liver disease as in healthy subjects.

We evaluated direct cost of different vaccination strategies by age group and number of vaccine doses (one or two). Of patients with a mean age of 47 years attending a general hospital located in an essentially urban community (group 2), seroprevalence of total anti-HAV antibodies was 80% for the overall population and 56% for patients under 40 years. Using equivalent item costs, strategy B (screening for antibodies then vaccinating negative subjects) is more economical for all ages and for both dose schemes. In a population of patients recently screened positive for HCV, our small sample showed that 60% of the population was immunized against HAV. Here using strategy B with a single vaccine dose induces an extra cost. These results should however be balanced against data concerning vaccination in HCV-positive patients which have demonstrated less efficacy of a single dose compared with complete vaccination [19]. Cost simulations for single-dose strategies would thus be less pertinent. The impact of HAV infection epidemiology on cost-effectiveness of anti-HAV vaccination in HCV-positive patients was recently demonstrated by Myers et al. [21]. In Canada, the economical strategy is abstention from vaccination. However the screening-vaccination strategy becomes cost effective when the seroprevalence of anti-HAV antibodies is in the 50-70% range [21]. If, after a few years the seroprevalence of anti-HAV antibodies should fall significantly, the vaccination strategy we propose on the basis of our results could become obsolete. Indeed, in a recent North American study [7] where the study population had a lower HAV seroprevalence than ours, the authors proposed systematic vaccination without prior screening for antibodies in all subjects under 40 years of age and systematic screening before vaccination in Afro-American patients and patients aged over 60 years, where the HAV seroprevalence is high [7].

In conclusion, the results of this study show that the seroprevalence of total anti-HAV antibodies in HCV-positive patients is about 76% and is comparable with the seroprevalence observed in the age-stratified general population. The cost-effective vaccination strategy in this population with a high anti-HAV seroprevalence would be screening first for the presence of total anti-HAV antibodies followed by complete vaccination in seronegative subjects. An evaluation of the overall costs of this vaccination is currently under way in a larger population.

ACKNOWLEDGEMENTS - The authors are grateful to A Ghazali, M. Artigues, R. Demontis, C. Biechmeyer for their participation in this study and Mrs M. Cavicchi for her help in preparing the manuscript.

RÉFÉRENCES